ArticleBMC pediatrics2026
Novel homozygous variant in ACSL5 gene causing Congenital Diarrhea and Enteropathy (CODE) with sustained therapeutic success: a case report.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital Diarrhea and Enteropathies (CODEs) are rare monogenic disorders with early-onset diarrhea, feeding intolerance, and malabsorption causing secondary failure to thrive (FTT). ACSL5 deficiency is an emerging CODE subtype linked to defective intestinal fatty acid metabolism and dysregulated satiety signaling. CASE PRESENTATION: A female infant presented with chronic diarrhea, postprandial vomiting, and severe growth faltering. First-line evaluations were unrevealing. Proband-only whole-exome sequencing (WES) identified a novel homozygous missense variant in ACSL5, NM_016234.4:c.1748G > A, p.(Gly583Asp) (OMIM #620357), absent from population/clinical databases; in the context of consanguinity and fitting phenotype, findings supported ACSL5-related CODE. A medium-chain triglyceride (MCT)-enriched, low-fat diet started at 8 months led to resolution of gastrointestinal symptoms within weeks and sustained catch-up growth. At 4 years, the child was asymptomatic with weight/height around the 50th percentiles and normal development.
conclusionsThis case broadens the clinical/variant spectrum of ACSL5-related enteropathy and highlights a dual mechanism, impaired intestinal long-chain fatty-acid activation with enteroendocrine dysregulation. Early exome sequencing and MCT-based nutrition can enable rapid symptom control and durable growth recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.